BLISS GVS PHARMA
|
BLISS GVS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.00 | 7.21 | 6.80 | 1.45 | 6.64 |
| CEPS(Rs) | 11.36 | 10.31 | 9.16 | 3.90 | 8.84 |
| DPS(Rs) | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 |
| Book NAV/Share(Rs) | 99.09 | 91.65 | 84.01 | 78.01 | 77.41 |
| Tax Rate(%) | 28.16 | 30.20 | 27.66 | 57.30 | 28.96 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.65 | 19.56 | 15.61 | 15.83 | 18.48 |
| EBIT Margin(%) | 16.52 | 16.07 | 15.49 | 7.88 | 19.29 |
| Pre Tax Margin(%) | 15.52 | 15.17 | 14.11 | 7.25 | 18.04 |
| PAT Margin (%) | 11.15 | 10.59 | 10.21 | 3.09 | 12.82 |
| Cash Profit Margin (%) | 14.78 | 14.02 | 12.69 | 5.41 | 15.80 |
| Performance Ratios | |||||
| ROA(%) | 7.18 | 6.90 | 6.78 | 2.12 | 7.03 |
| ROE(%) | 9.01 | 8.89 | 9.11 | 2.88 | 9.64 |
| ROCE(%) | 12.29 | 12.15 | 12.22 | 6.37 | 12.49 |
| Asset Turnover(x) | 0.64 | 0.65 | 0.66 | 0.68 | 0.55 |
| Sales/Fixed Asset(x) | 1.62 | 1.66 | 1.87 | 2.38 | 2.06 |
| Working Capital/Sales(x) | 1.25 | 1.18 | 1.49 | 1.37 | 1.03 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.62 | 0.60 | 0.53 | 0.42 | 0.49 |
| Receivable days | 189.93 | 187.07 | 188.89 | 209.14 | 319.89 |
| Inventory Days | 55.03 | 52.48 | 55.12 | 54.42 | 54.72 |
| Payable days | 58.40 | 70.38 | 81.40 | 77.87 | 90.85 |
| Valuation Parameters | |||||
| PER(x) | 14.69 | 15.63 | 10.47 | 53.04 | 14.86 |
| PCE(x) | 10.35 | 10.92 | 7.78 | 19.72 | 11.16 |
| Price/Book(x) | 1.19 | 1.23 | 0.85 | 0.99 | 1.28 |
| Yield(%) | 0.43 | 0.44 | 0.70 | 0.65 | 0.51 |
| EV/Net Sales(x) | 1.35 | 1.37 | 0.98 | 0.97 | 1.72 |
| EV/Core EBITDA(x) | 6.72 | 5.86 | 5.46 | 4.84 | 7.72 |
| EV/EBIT(x) | 8.20 | 8.49 | 6.33 | 12.31 | 8.91 |
| EV/CE(x) | 0.98 | 1.00 | 0.75 | 0.65 | 1.07 |
| M Cap / Sales | 1.53 | 1.53 | 0.99 | 1.07 | 1.76 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.13 | 2.48 | 0.55 | 29.50 | -16.26 |
| Core EBITDA Growth(%) | -9.02 | 32.75 | -9.83 | 16.51 | -20.86 |
| EBIT Growth(%) | 8.06 | 6.31 | 97.66 | -47.11 | -18.43 |
| PAT Growth(%) | 10.64 | 6.31 | 231.80 | -68.74 | -22.34 |
| EPS Growth(%) | 11.00 | 5.94 | 368.98 | -78.15 | -29.58 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.09 | 0.11 | 0.13 | 0.15 |
| Current Ratio(x) | 4.77 | 5.15 | 3.61 | 3.33 | 3.76 |
| Quick Ratio(x) | 4.04 | 4.40 | 3.08 | 2.80 | 3.27 |
| Interest Cover(x) | 16.47 | 17.91 | 11.23 | 12.42 | 15.38 |
| Total Debt/Mcap(x) | 0.06 | 0.07 | 0.13 | 0.13 | 0.12 |
Compare Financial Ratios of peers of BLISS GVS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BLISS GVS PHARMA | ₹1,792.1 Cr | 1.7% | 9.3% | 32.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,370.0 Cr | 1.2% | 5.5% | 0.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,802.0 Cr | -1.8% | -3.1% | 8.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹125,841.0 Cr | -2% | 2.8% | 19.2% | Stock Analytics | |
| CIPLA | ₹121,481.0 Cr | -0.7% | -8.6% | 2.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,220.0 Cr | -1.5% | -4.3% | 2.5% | Stock Analytics | |
BLISS GVS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BLISS GVS PHARMA | 1.7% |
9.3% |
32.4% |
| SENSEX | -0.1% |
0.6% |
9.8% |
You may also like the below Video Courses
